recommend
earli
antimicrobi
treatment
childhood
pneumonia
eff
ectiv
reduc
childhood
mortal
last
major
revis
year
ago
emerg
antimicrobi
resist
new
pneumonia
pathogen
new
drug
prompt
assembl
intern
panel
review
literatur
childhood
pneumonia
develop
evidencebas
recommend
empir
treatment
nonsever
pneumonia
among
children
manag
fi
rstlevel
health
provid
treatment
target
bacteri
caus
like
lead
sever
diseas
includ
streptoccocu
pneumonia
haemophilu
infl
uenza
best
fi
rstline
agent
amoxicillin
given
twice
daili
day
although
cotrimoxazol
may
altern
set
treatment
failur
defi
ned
child
develop
sign
warrant
immedi
referr
decreas
respiratori
rate
h
therapi
failur
occur
indic
immedi
referr
exist
possibl
explan
failur
systemat
determin
includ
nonadher
therapi
altern
diagnos
failur
fi
rstline
agent
remain
possibl
explan
suitabl
secondlin
agent
includ
highdos
amoxicillinclavulan
acid
without
aff
ordabl
macrolid
children
year
age
year
clinic
pneumonia
occur
estim
million
children
age
year
caus
approxim
fi
fth
death
among
children
lowincom
nation
reduc
morbid
mortal
pneumonia
children
guidelin
current
known
integr
manag
childhood
ill
imci
develop
partner
fi
rstlevel
health
system
imci
implement
mani
organis
reduc
mortal
eff
ectiv
although
implement
improv
guidelin
includ
recommend
case
manag
acut
respiratori
ill
indic
referr
need
specifi
appropri
antimicrobi
agent
referr
need
recommend
treatment
pneumonia
provid
critic
guidanc
fi
rstlevel
healthcar
worker
worldwid
last
major
revis
year
old
fi
rst
recommend
respiratori
diseas
case
manag
publish
memorandum
memorandum
aim
encourag
systemat
approach
manag
children
possibl
pneumonia
resourcepoor
set
base
simpl
algorithm
empir
treatment
recommend
agent
includ
drug
avail
time
public
intramuscular
oral
drug
list
procain
penicillin
ampicillin
erythromycin
cotrimoxazol
sulfamethoxypyridazin
note
yet
littl
experi
cotrimoxazol
secondlin
agent
use
children
still
ill
h
includ
chloramphenicol
oxacillin
publish
revis
document
much
experi
gain
casemanag
approach
empir
treatment
treatment
nonsever
pneumonia
fi
rstlevel
health
facil
document
recommend
oral
cotrimoxazol
prefer
agent
inject
procain
penicillin
oral
amoxicillin
altern
technic
updat
imci
guidelin
recommend
oral
amoxicillin
mgkg
per
dose
two
divid
dose
cotrimoxazol
mgkg
trimethoprim
per
dose
two
divid
dose
treatment
nonsever
pneumonia
antimicrobi
resist
cotrimoxazol
high
oral
amoxicillin
prefer
past
decad
variou
organis
issu
recommend
paediatr
pneumonia
treatment
recommend
primarili
intend
highincom
middleincom
nation
new
inform
antimicrobi
resist
chang
epidemiolog
pneumonia
avail
broader
rang
fi
rstline
secondlin
antimicrobi
agent
provid
impetu
updat
recommend
antimicrobi
treatment
nonsever
pneumonia
among
children
assess
fi
rstlevel
health
provid
often
basic
health
train
depart
child
adolesc
health
develop
select
assembl
panel
review
current
literatur
childhood
pneumonia
defi
ne
appropri
antimicrobi
agent
treatment
nonsever
pneumonia
specifi
calli
ask
defi
ne
appropri
fi
rstline
antimicrobi
agent
treatment
failur
chang
therapi
appropri
secondlin
antimicrobi
agent
intern
panel
consist
nine
clinician
research
experi
defi
ning
treat
review
pneumonia
among
children
variou
set
commun
regular
confer
call
email
review
avail
evid
discuss
issu
interpret
aetiolog
studi
result
antimicrobi
resist
data
initi
focu
identifi
appropri
fi
rstline
secondlin
antimicrobi
agent
empir
treatment
nonsever
pneumonia
children
fi
rstlevel
healthcar
worker
howev
determin
address
secondlin
therapi
defi
nition
treatment
failur
determin
chang
therapi
requir
panel
literatur
search
done
gener
foundat
recommend
result
appropri
fi
rstline
secondlin
antimicrobi
agent
webtabl
similar
obtain
cochran
review
evid
collect
focu
public
januari
date
last
recommend
septemb
search
pubm
embas
cochran
central
registrar
control
trial
addit
bibliographi
relev
articl
author
record
search
term
pneumonia
child
childhood
pediatr
paediatr
antibiot
trial
cohort
limit
avail
articl
english
english
abstract
includ
children
pneumonia
age
year
studi
select
antimicrobi
agent
articl
assess
one
antimicrobi
agent
seven
articl
assess
diff
erent
durat
dose
antimicrobi
agent
use
randomis
control
trial
includ
review
articl
exclud
treatment
failur
data
avail
outcom
exclus
enrol
children
sever
pneumonia
articl
present
result
children
spectrum
diagnosi
eg
sinus
otiti
media
pneumonia
result
children
pneumonia
includ
possibl
articl
provid
basi
along
panel
experi
recommend
initi
recommend
draft
circul
broader
group
review
comment
broader
group
includ
expert
experi
treatment
epidemiolog
pneumonia
well
repres
region
offi
ce
tabl
outlin
recommend
develop
strength
major
recommend
qualiti
support
evid
base
grade
recommend
assess
develop
evalu
grade
system
grade
qualiti
evid
categori
includ
high
intermedi
low
low
determin
panel
review
literatur
studi
avail
review
except
observ
natur
rather
blind
randomis
trial
therefor
grade
qualiti
evid
rare
higher
intermedi
review
broader
group
strength
recommend
determin
panel
member
amoxicillin
prefer
initi
antimicrobi
agent
treatment
nonsever
pneumonia
dose
amoxicillin
mgkg
per
day
two
divid
dose
treatment
cours
area
low
hiv
preval
day
area
high
hiv
preval
situat
local
evid
clearli
indic
infrequ
resist
cotrimoxazol
mgkg
trimethoprim
two
divid
dose
may
accept
altern
pneumonia
strictli
speak
patholog
diagnosi
determin
clinic
mean
radiolog
consolid
commonli
use
surrog
often
feasibl
fi
rstlevel
health
facil
review
valid
identifi
children
specifi
c
treatment
need
need
antimicrobi
therapi
referr
higher
level
care
nonsever
pneumonia
diagnos
child
cough
diffi
culti
breath
accompani
tachypnoea
defi
ned
respiratori
rate
least
breath
per
min
child
age
month
least
breath
per
min
infant
age
month
use
criteria
identifi
es
children
pneumonia
need
antimicrobi
therapi
children
age
month
requir
immedi
referr
sign
sever
sever
pneumonia
lower
chest
indraw
central
cyanosi
stridor
calm
imcidefi
ned
danger
sign
inabl
drink
breastfe
convuls
persist
vomit
lethargi
unconsci
children
age
less
month
pneumonia
defi
nition
sever
pneumonia
due
higher
risk
mortal
thu
requir
referr
identifi
cation
predict
like
organ
caus
pneumonia
import
step
determin
appropri
antimicrobi
therapi
despit
import
understand
aetiolog
pneumonia
recent
studi
done
resourcepoor
set
area
high
hiv
preval
use
studi
done
gener
use
one
two
approach
vaccin
probe
method
comprehens
diagnost
test
protocol
vaccin
probe
studi
may
provid
best
possibl
estim
pathogenspecifi
c
pneumonia
burden
limit
insensit
diagnost
test
practic
howev
studi
extrem
costli
gener
estim
role
vaccinetyp
strain
pathogen
often
focu
sever
hospitalis
pneumonia
case
contrast
studi
incorpor
wide
rang
diagnost
test
er
possibl
detect
mani
pathogen
diagnost
test
use
howev
often
insensit
sometim
specifi
c
limit
data
qualiti
directli
obtain
specimen
site
infect
lung
aspir
antimicrobi
administr
potenti
goldstandard
approach
children
produc
posit
result
appropri
select
case
accord
review
studi
although
approach
produc
rel
high
yield
limit
peripher
lobar
pneumonia
may
select
decreas
yield
sever
pathogen
therefor
may
repres
sever
pneumonia
result
aetiolog
studi
requir
cautiou
interpret
estim
proport
pneumonia
caus
diff
erent
pathogen
vari
sensit
culturebas
techniqu
identifi
bacteria
compromis
previou
antimicrobi
administr
often
assess
antimicrobi
exposur
cultur
common
measur
result
culturebas
studi
may
signifi
cantli
underestim
organ
sensit
commonli
prescrib
antimicrobi
agent
streptococcu
pneumonia
haemophilu
infl
uenza
overestim
organ
staphylococcu
aureu
although
limit
list
numer
success
treatment
ultim
depend
target
caus
agent
therefor
despit
limit
estim
base
proport
radiograph
confi
rmed
pneumonia
prevent
vaccin
vaccin
vaccin
probe
studi
support
lung
aspir
studi
haemophilu
infl
uenza
increas
use
highli
effi
caciou
vaccin
diseas
h
infl
uenza
type
b
may
decreas
role
pathogen
nontyp
b
may
play
greater
role
nonsever
pneumonia
type
b
found
signifi
cant
caus
pneumonia
vaccin
probe
studi
except
one
lung
aspir
studi
staphylococcu
aureu
present
clinic
sever
necrotis
pneumonia
rapid
progress
nontyphoid
salmonella
bacteraemia
may
present
featur
consist
clinic
diagnosi
pneumonia
estim
base
studi
tropic
africa
associ
nonsever
pneumonia
malariaendem
region
africa
mycoplasma
pneumonia
limit
diagnost
capac
lowincom
countri
proport
pneumonia
associ
infect
increas
age
greatest
burden
children
age
year
assumpt
infect
caus
signifi
cant
morbid
mortal
lack
evid
either
valid
invalid
chlamydophila
pneumonia
limit
diagnost
capac
lowincom
countri
proport
pneumonia
associ
infect
increas
age
greatest
burden
children
age
year
poor
qualiti
serolog
data
young
children
moraxella
catarrhali
often
focu
pneumonia
microbiolog
studi
klebsiella
pneumonia
one
studi
note
higher
proport
children
previou
antimicrobi
use
rare
except
malnourish
children
respiratori
syncyti
viru
particularli
import
young
infant
infl
uenza
virus
import
caus
throughout
age
rang
increasingli
document
tropic
adenovirus
limit
diagnost
test
use
poor
insensit
test
parainfl
uenza
virus
occurr
altern
year
mean
singleyear
studi
limit
valu
human
metapneumoviru
recent
welldocu
caus
pneumonia
other
includ
bocaviru
coronavirus
rhinovirus
recent
pcrbase
studi
consist
identifi
new
virus
signifi
canc
remain
defi
ned
estim
aetiolog
burden
wide
rang
variat
may
real
due
increas
proport
aetiolog
due
high
hiv
preval
well
season
eg
infl
uenza
geograph
eg
salmonella
variabl
howev
primari
sourc
variabl
may
due
measur
either
enrol
criteria
hospitalis
versu
outpati
enrol
inadequ
diagnost
test
blood
cultur
low
yield
eg
blood
cultur
misclassifi
cation
eg
urin
antigen
test
previou
antimicrobi
administr
also
may
result
underestim
agent
poor
laboratori
qualiti
also
play
import
part
zero
percentag
except
case
klebsiella
often
due
lack
diagnost
test
use
poor
insensit
test
import
reason
failur
consist
identifi
pathogen
although
case
true
season
geograph
variat
may
contribut
review
estim
common
pathogen
caus
pneumonia
children
requir
determin
appropri
empir
antimicrobi
therapi
wherea
recommend
nonsever
pneumonia
import
rememb
aetiolog
studi
usual
enrol
hospit
inpati
sever
pneumonia
common
bacteri
viral
caus
pneumonia
pathogen
shown
tabl
estim
includ
rather
broad
rang
plausibl
aetiolog
fraction
studi
lack
comprehens
investig
viral
caus
pneumonia
studi
provid
estim
approxim
rang
pneumonia
acquir
commun
posit
viral
diagnost
test
identifi
cation
viru
necessarili
impli
pneumonia
exclus
caus
viru
viral
bacteri
agent
may
coexist
make
role
pathogen
uncertain
recommend
nonsever
pneumonia
limit
lack
data
caus
pneumonia
among
children
treat
outsid
hospit
describ
howev
import
goal
treatment
nonsever
pneumonia
prevent
progress
sever
pneumonia
therefor
direct
antimicrobi
therapi
nonsever
pneumonia
toward
pathogen
known
caus
sever
pneumonia
believ
appropri
pathogen
pneumonia
h
infl
uenza
promin
treatabl
caus
sever
pneumonia
fi
rstline
antimicrobi
therapi
histor
direct
primarili
pathogen
approach
target
two
aetiolog
agent
repeatedli
shown
eff
ectiv
reduc
pneumonia
morbid
overal
mortal
studi
clinic
experi
past
year
alter
empir
fi
rstline
treatment
better
cover
atyp
agent
aureu
nontyphoid
salmonella
other
might
consid
theoret
ground
base
abovereferenc
studi
approach
lack
evid
would
reduc
morbid
mortal
mani
studi
compar
effi
caci
diff
erent
antimicrobi
agent
treat
pneumonia
children
webtabl
howev
despit
larg
number
studi
limit
small
sampl
size
lack
power
conclus
show
noninferior
studi
also
hamper
inabl
accur
consist
defi
ne
treatment
failur
larg
due
limit
resourc
avail
fi
eld
interpret
also
limit
socal
pollyanna
phenomenon
set
antimicrobi
agent
compar
standard
agent
potenti
danger
subset
bacteri
case
intend
target
studi
dilut
inclus
milder
selflimit
viral
diseas
result
poor
antimicrobi
agent
seem
effi
caciou
superior
antimicrobi
agent
seem
less
effi
caciou
standard
agent
note
marchant
colleagu
set
otiti
media
lack
bacteri
endpoint
complic
understand
clinic
relev
antimicrobi
resist
manag
pneumonia
commun
percept
clinic
relev
amoxicillin
macrolid
cotrimoxazol
resist
oral
outpati
manag
pneumonia
base
failur
oral
agent
erad
resist
pneumonia
middl
ear
although
strau
colleagu
suggest
cotrimoxazol
higher
failur
rate
sever
pneumonia
treatment
amoxicillin
role
resist
unclear
even
though
resist
frequent
propos
explan
subanalysi
show
signifi
cant
increas
failur
among
cotrimoxazoleresist
pneumonia
h
infl
uenza
treat
cotrimoxazol
pneumonia
studi
describ
clinic
impact
cotrimoxazol
resist
treatment
pneumonia
invitro
resist
cotrimoxazol
correl
poor
clinic
outcom
treatment
pathogen
acut
otiti
media
trial
treatment
acut
otiti
media
measur
bacteriolog
failur
use
tympanocentesi
compar
middleear
fl
uid
cultur
therapi
show
bacteri
erad
treatment
one
tympanocentesi
studi
cotrimoxazol
resist
result
higher
rate
bacteriolog
failur
h
infl
uenza
pneumonia
caveat
middleear
fl
uid
concentr
mani
drug
substanti
lower
compar
lung
concentr
therefor
antimicrobi
agent
use
therapi
acut
otiti
media
may
perform
poorli
strain
decreas
suscept
antimicrobi
use
pneumonia
therapi
caveat
avail
data
suggest
vitro
cotrimoxazol
resist
meaning
clinic
circumst
conclus
relev
pneumonia
import
implic
countri
cotrimoxazol
resist
common
firstlin
antimicrobi
agent
eff
ectiv
reliabl
wide
avail
aff
ordabl
resourcepoor
set
technic
updat
imci
guid
line
recommend
oral
amoxicillin
cotrimoxazol
fi
rstline
treatment
nonsever
pneumonia
low
cost
wide
spectrum
coverag
histor
cotrimoxazol
amoxicillin
evalu
treatment
nonsever
pneumonia
two
studi
done
pakistan
compar
amoxicillin
cotrimoxazol
children
age
year
absolut
diff
erenc
treatment
failur
children
treatment
failur
take
cotrimoxazol
rel
amoxicillin
illustr
fi
gure
studi
strau
colleagu
includ
children
sever
nonsever
pneumonia
wherea
studi
catchup
cotrimoxazol
amoxicillin
trial
children
year
pneumonia
studi
group
includ
children
nonsever
pneumonia
durat
dosag
amoxicillin
therapi
assess
summaris
consult
meet
report
two
clinic
trial
india
pakistan
examin
short
versu
standard
amoxicillin
treatment
cours
pneumonia
show
equal
eff
ectiv
two
durat
shorten
cours
well
studi
area
high
hiv
preval
substanti
greater
burden
sever
bacteri
pneumonia
among
hivinfect
person
exist
prudenc
indic
shorten
treatment
cours
studi
implement
set
variat
amoxicillin
dose
well
studi
treatment
childhood
pneumonia
one
studi
children
compar
day
amoxicillin
mgkg
versu
mgkg
dose
show
signifi
cant
diff
erenc
treatment
failur
day
initi
therapi
treatment
failur
defi
ned
develop
lower
chestwal
indraw
central
cyanosi
stridor
calm
imcidefi
ned
danger
sign
time
child
ill
persist
rais
respiratori
rate
h
h
area
high
hiv
preval
treatment
failur
previous
vagu
defi
ned
ie
respiratori
rate
persist
ageappropri
imci
cutoff
deterior
day
therapi
deterior
develop
chest
indraw
central
cyanosi
stridor
calm
imcidefi
ned
danger
sign
child
deterior
sign
symptom
tradit
assess
schedul
followup
visit
h
initi
therapi
howev
basi
result
studi
pakistan
h
may
accept
countri
low
hiv
preval
result
replic
lowincom
countri
particularli
high
hiv
preval
believ
children
persist
rais
respiratori
rate
indic
immedi
referr
undergo
brief
systemat
assess
determin
whether
secondlin
therapi
would
benefi
cial
brief
systemat
assess
use
children
fail
therapi
nonsever
hospit
assess
common
agent
may
respons
least
third
outpati
pneumonia
treatment
failur
uncommon
agent
may
respons
minor
fraction
rare
agent
probabl
respons
occasion
treatment
failur
global
uncommon
agent
may
common
certain
geograph
area
although
uncommon
caus
pneumonia
treatment
failur
global
base
data
heff
elfi
nger
et
al
discuss
panel
base
clinic
experi
referr
next
level
facil
instead
hospit
may
occasion
appropri
depend
resourc
facil
suspect
condit
literatur
describ
treatment
failur
prompt
chang
therapi
treatment
failur
may
occur
mani
reason
one
use
drug
infect
agent
suscept
mani
reason
describ
tabl
requir
assess
hospit
specifi
c
therapi
child
develop
sign
indic
need
immedi
referr
treatment
initi
refer
immedi
believ
children
fail
improv
requir
immedi
referr
systemat
assess
chang
antimicrobi
agent
assess
begin
fi
rstlevel
health
worker
determin
whether
failur
due
inabl
unwilling
take
medicin
appropri
health
worker
believ
child
taken
antimicrobi
agent
correctli
condit
result
treatment
failur
consid
initi
assess
health
worker
indic
consider
unlik
referr
warrant
secondlin
agent
expand
coverag
assess
fi
rstlevel
health
worker
may
guid
algorithm
effi
caci
algorithm
shown
assess
initi
case
manag
acut
respiratori
ill
guidelin
howev
awar
studi
show
effi
caci
algorithm
systemat
assess
child
improv
therapi
figur
show
exampl
algorithm
develop
us
aim
simpl
health
worker
use
accur
consist
address
major
caus
treatment
failur
valid
tool
ere
pure
exampl
set
fi
rstlevel
health
provid
children
initi
treat
amoxicillin
persist
rais
respiratori
rate
indic
referr
receiv
highdos
amoxicillin
clavulan
acid
mgkg
per
day
amoxicillin
secondlin
therapi
provid
coverag
major
pathogen
like
caus
sever
diseas
treatment
cours
prescrib
secondlin
antimicrobi
agent
children
year
age
aff
ordabl
macrolid
azalid
eg
mgkg
erythromycin
four
divid
dose
day
may
ad
exist
regimen
treatment
cours
children
fail
fi
rstline
treatment
cotrimoxazol
recommend
switch
cours
amoxicillin
mgkg
defi
ne
secondlin
antimicrobi
agent
use
set
treatment
failur
indic
immedi
referr
present
ie
imci
danger
sign
lower
chest
indraw
stridor
central
cyanosi
reason
treatment
failur
exclud
studi
identifi
ed
assess
secondlin
antimicrobi
agent
therefor
secondlin
antimicrobi
agent
logic
select
treat
organ
fail
fi
rstline
therapi
wherea
substanti
proport
failur
fi
rstline
agent
may
due
mild
selflimit
viral
infect
secondlin
agent
ensur
coverag
resist
organ
cover
broader
rang
organ
would
treat
typic
fi
rstline
agent
set
coverag
may
extend
includ
aureu
nontyphoid
salmonella
secondlin
antimicrobi
agent
broaden
enhanc
coverag
set
treatment
failur
recommend
best
secondlin
anti
microbi
integr
manag
childhood
ill
guidelin
follow
child
assess
malnutrit
hiv
set
high
preval
fi
gure
ere
exampl
algorithm
develop
yyymultipl
trial
strong
trial
evid
yysom
trial
good
evid
yminim
trial
evid
pkpd
properti
use
help
determin
suscept
breakpoint
antimicrobi
agent
therefor
agent
like
effi
caci
pkpd
properti
drug
class
follow
aminopenicillin
penicillin
cephalosporinstim
minimum
inhibitori
concentr
mic
macrolid
fl
uoroquinolonesarea
curvem
nonor
medic
includ
administr
syring
needl
cost
cours
day
dose
base
kg
child
except
intramuscular
penicillin
ceftriaxon
cost
includ
drug
cost
includ
needl
administr
although
drug
cost
may
critic
import
consider
may
accept
secondlin
antimicrobi
agent
expens
fi
rstline
agent
treatment
cours
price
us
use
cutoff
assess
agent
accept
tabl
appropri
secondlin
agent
must
enhanc
coverag
alreadi
provid
fi
rstline
agent
parenter
antimicrobi
agent
often
use
hospit
set
rare
use
outpati
clinic
lowincom
countri
percept
patient
provid
parenter
agent
alway
eff
ectiv
oral
agent
diffi
cult
correct
therefor
introduct
parenter
antimicrobi
agent
ceftriaxon
peripher
set
may
impract
reason
situat
child
initi
take
cotrimoxazol
correct
pneumonia
treatment
dose
prefer
secondlin
agent
would
oral
amoxicillin
mgkg
two
divid
dose
day
fi
rstline
agent
amoxicillin
second
antimicrobi
agent
choic
expand
spectrum
enhanc
coverag
use
highdos
amoxicillinclavulan
acid
mgkg
daili
divid
dose
amoxicillin
maximum
mgkg
clavulan
acid
daili
anoth
possibl
enhanc
activ
betalactamaseproduc
h
infl
uenza
resist
pneumonia
would
cover
atyp
bacteria
oral
secondgener
thirdgener
cephalosporin
antimicrobi
agent
expens
improv
coverag
betalactamaseproduc
h
infl
uenza
cefuroxim
cefi
xime
reason
price
although
activ
highdos
amoxicillinclavulan
acid
pneumonia
addit
agent
provid
coverag
pneumonia
c
pneumonia
oral
chloramphenicol
palmit
less
desir
secondlin
agent
nonsever
pneumonia
antimicrobi
agent
bacteriostat
wide
rang
potenti
pathogen
bactericid
pneumonia
h
infl
uenza
although
resist
chloramphenicol
bonemarrow
toxic
includ
revers
dosedepend
suppress
well
aplast
anaemia
latter
occur
approxim
one
cours
although
chloramphenicol
activ
wide
rang
causal
agent
inexpens
potenti
bonemarrow
toxic
limit
use
fi
rstline
agent
univers
secondlin
agent
panel
member
express
reserv
agent
safeti
concern
use
oral
agent
mild
diseas
outpati
set
also
import
concern
drive
resist
set
parenter
chloramphenicol
may
sole
agent
treat
meningococc
mening
oral
chloramphenicol
may
use
children
intramuscular
antimicrobi
agent
avail
immedi
transport
higher
level
care
hospit
possibl
although
tetracyclin
appropri
drug
treatment
paediatr
infect
small
risk
associ
sideeff
ect
outweigh
potenti
advantag
widespread
use
drug
nonsever
pneumonia
treatment
similarli
respiratori
fl
uoroquinolon
optimum
secondlin
drug
outpati
pneumonia
theoret
risk
toxic
eff
ect
young
children
well
measur
risk
promot
resist
valuabl
class
antimicrobi
agent
azithromycin
clarithromycin
erythromycin
reason
price
role
agent
limit
extend
antimicrobi
spectrum
atyp
organ
agent
rel
inact
h
infl
uenza
increas
resist
among
pneumonia
therefor
aff
ordabl
macrolid
azalid
may
consid
child
better
worsen
time
reassess
year
age
atyp
infect
like
erythromycin
may
use
three
four
divid
dose
treatment
cours
daili
dose
mgkg
advantag
erythromycin
azithromycin
clarithromycin
includ
lowcost
wide
avail
disadvantag
includ
gastrointestin
disturb
frequent
dose
macrolid
azalid
also
indic
document
allergi
penicillin
betalactam
agent
cotrimoxazol
consid
secondlin
agent
cotrimoxazol
resist
pneumonia
often
coexist
penicillin
resist
fi
rstline
agent
use
amoxicillin
addit
cotrimoxazol
would
probabl
benefi
gener
recommend
may
need
modifi
ed
children
live
area
hiv
malaria
common
referr
possibl
countri
introduc
algorithm
empir
use
fi
rstlevel
health
worker
identifi
area
consid
modifi
cation
recommend
special
attent
requir
region
hiv
preval
consist
exceed
least
one
defi
ned
subpopul
case
much
eastern
central
southern
africa
certain
region
asia
latin
america
high
preval
area
hiv
counsel
test
recommend
children
age
year
seen
paediatr
health
servic
burden
hivassoci
pneumonia
region
substanti
one
studi
area
hivposit
preval
among
children
age
year
report
hospitalis
pneumonia
pneumonia
death
occur
among
hivposit
children
prophylact
cotrimoxazol
shown
improv
surviv
reduc
pneumoniarel
death
hivinfect
children
therefor
administ
children
present
pneumonia
assess
symptomat
hiv
infect
area
hiv
publichealth
problem
test
indic
use
method
describ
horwood
colleagu
children
live
area
high
hiv
preval
clinic
suspicion
diagnosi
hiv
infect
present
nonsever
pneumonia
recommend
treatment
amoxicillin
irrespect
cotrimoxazol
prophylaxi
statu
pneumocysti
jirovecii
known
caus
sever
progress
pneumonia
especi
among
children
age
month
role
nonsever
pneumonia
hivinfect
children
evalu
part
review
child
fail
fi
rstline
therapi
nonsever
pneumonia
child
refer
hospit
manag
guidelin
includ
hiv
test
broadspectrum
parenter
antimicrobi
agent
final
children
high
preval
area
without
clinic
suspicion
diagnosi
hiv
infect
fail
improv
fi
rstline
therapi
treat
accord
standard
recommend
outlin
review
clinic
overlap
malaria
pneumonia
children
well
recognis
symptomat
malaria
may
clinic
featur
consist
diagnosi
pneumonia
wherea
children
pneumonia
may
coincident
malaria
parasitaemia
cotrimoxazol
therapi
nonsever
pneumonia
recommend
countri
malaria
diagnosi
unavail
fi
rstlevel
facil
part
cotrimoxazol
activ
malaria
common
bacteri
caus
pneumonia
children
howev
cotrimoxazol
fi
rstline
antimalaria
drug
amoxicillin
antimalari
activ
prefer
cotrimoxazol
fi
rstline
therapi
nonsever
pneumonia
therefor
child
clinic
featur
nonsever
pneumonia
malaria
exclud
recommend
fi
rstline
therapi
malaria
pneumonia
prescrib
caution
exercis
use
erythromycin
secondlin
agent
mefl
oquin
halofantrin
prescrib
malaria
due
increas
risk
arrhythmia
complic
malaria
sever
anaemia
like
pneumonia
caus
rapid
breath
malariaendem
region
children
present
rapid
breath
assess
sever
anaemia
laboratori
assess
avail
mark
pallor
may
assess
examin
palm
hand
nail
bed
conjunctiva
child
clinic
diagnosi
pneumonia
also
sever
anaemia
refer
hospit
assess
child
fail
treatment
meet
criteria
referr
transport
assess
centr
provid
intens
therapi
howev
referr
imposs
area
situat
child
receiv
treatment
agent
provid
broader
coverag
high
activ
pathogen
caus
sever
pneumonia
antimicrobi
agent
includ
inject
antimicrobi
agent
ceftriaxon
penicillingentamicin
chloramphenicol
whorecommend
systemat
casemanag
approach
greatli
reduc
mortal
children
pneumonia
updat
recommend
identifi
amoxicillin
prefer
fi
rstline
agent
specifi
approach
chang
appropri
secondlin
agent
event
treatment
failur
tabl
aim
improv
treatment
protocol
fi
rstlevel
health
provid
children
nonsever
pneumonia
recommend
develop
use
avail
evid
treatment
children
pneumonia
lowincom
countri
evid
basi
recommend
limit
research
need
sever
area
area
includ
improv
understand
aetiolog
pneumonia
children
sever
nonsever
use
optimum
diagnost
test
better
understand
reason
treatment
failur
determin
best
systemat
method
assess
treatment
failur
fi
rstlevel
health
worker
meantim
adapt
gener
recommend
fi
countryspecifi
c
treatment
algorithm
help
resolv
uncertainti
surround
appropri
manag
young
children
nonsever
pneumonia
describ
detail
method
section
declar
confl
ict
interest
